Onconetix
Manufacturing · Ohio, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
201 E 5th St Ste 190, Cincinnati, Ohio, ...Phone Number
(513) 620-4101Website
www.onconetix.comRevenue
<$5 MillionStock Symbol
ONCOIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Onconetix
Onconetix, Inc. is a commercial-stage biotechnology company headquartered in Cincinnati, Ohio, with operations in Zurich, Switzerland through its subsidiary Proteomedix AG. The company develops and commercializes diagnostic and therapeutic solutions for men’s health and oncology, particularly prostate cancer and benign prostatic hyperplasia (BPH). Its portfolio includes Proclarix, a CE-IVD certified blood test for prostate cancer detection, and Entadfi, an FDA-approved oral therapy for BPH. Onconetix also pursues licensing partnerships and clinical validation studies to expand its technologies in the U.S. and European markets.Explore more
Popular SearchesOnconetixOnconetix IncSIC Code 28,283NAICS Code 32,325Ticker NASDAQ:ONCOShow moreOnconetix Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Onconetix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check out if Onconetix is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Onconetix
Product Launch: Get notified when Onconetix launches new products
Check if Onconetix has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Onconetix recently announced quarterly report
Click to see if Onconetix had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Onconetix has new funding data
Onconetix, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Onconetix as Masked Content
Find more new buyers
Onconetix financials insights
Gather financial insights about Onconetix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series C
$2M
2025
Stock/Share Issuance
$13M
Most Recent Scoops
Lateral Move
Executive Move
Executive Moves, Lateral Move
Executive Move
Samuel Dorf, has been appointed to serve on the Board of Directors for the organization as Director.
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
New Hire
Executive Move
Executive Moves, New Hire
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Onconetix News & Media
Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG
Proteomedix Co-Founder and Proclarix® Co-Developer Returns to Company’s Board; Thomas Meier, PhD Re-Elected as Chairman at Annual General MeetingOnconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation
Realbotix Robots and AI to Deploy in Evidence-Based Pilot Designed to Improve Wellbeing and Address Loneliness Among Older Adults in UK Care Settings; Realbotix Becomes Accredited Supplier on Bloom’s Public Sector Marketplace; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp.Onconetix Highlights Realbotix’s Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District
Salamanca City Central School District on Seneca Nation Reservation to Deploy Optio and Realbotix M-Series Humanoid Robot; Pilot to Expand to Approximately 500 High School Students in Fall 2026; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp.Onconetix, Inc. Announces 1-for-10 Reverse Stock Split
CINCINNATI, Ohio, May 19, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for oncology, today announced that its Board of Directors (the “Board of Directors” or “Board”) has approved a 1-for-10 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on May 21, 2026.
Read more news
Top Manufacturing Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Onconetix
Sign Up For FreeTo access detailed company insights
Onconetix, Inc. is a commercial-stage biotechnology company headquartered in Cincinnati, Ohio, with operations in Zurich, Switzerland through its subsidiary Proteomedix AG. The company develops and commercializes diagnostic and therapeutic solutions for men’s health and oncology, particularly prostate cancer and benign prostatic hyperplasia (BPH).... Read More
